Electra Therapeutics Reports Third Quarter 2026 Financial Results and Recent Portfolio Highlights

Rhea-AI Summary

Electra Therapeutics (ETRA) reported a third-quarter 2026 net loss of $23.9 million while advancing ipsoprubart and ELA822 clinical programs. Research and development expenses were $17.3 million; general and administrative expenses were $7.8 million. Cash, cash equivalents and marketable securities totaled $402.5 million at September 30, including $320.0 million in net IPO proceeds. Electra expects funding to support planned operations into 2029.

Ipsoprubart's Phase 1b trial reported 100% eight-week survival and 100% week-four response in 12 frontline patients with malignancy-associated secondary hemophagocytic lymphohistiocytosis, a severe inflammatory syndrome. Electra expects registrational enrollment completion and initial T/NK malignancy trial data in the second half of 2027. ELA822 healthy-volunteer data are expected in the first half of 2027, with a patient trial planned for mid-2027, subject to regulatory approval.

10 points · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 5 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point$350 million IPO completed, providing $320.0 million in net proceeds after offering expenses. 59% of market cap
• Moderate point$402.5 million in cash, cash equivalents and marketable securities held at September 30, 2026.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Cash runway into 2029 expected by Electra for planned operations.
• Moderate point100% eight-week survival and 100% week-four response reported in 12 frontline malignancy-associated HLH patients; ipsoprubart was generally well tolerated.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Ipsoprubart registrational enrollment completion expected in the second half of 2027 across SURPASS and COMPASS.

5 minor points

• Minor pointEight objective tumor responses, including seven complete responses, observed among eight assessable sHLH patients with underlying lymphomas.
• Minor point. Forward-looking: it has not happened yet and may not happen.Ipsoprubart Phase 1 T/NK malignancy data expected in the second half of 2027.
• Minor pointELA822 nonclinical models showed reduced tissue inflammation and improvements in disease activity and survival.
• Minor point. Forward-looking: it has not happened yet and may not happen.ELA822 healthy-volunteer Phase 1 trial initiated in September 2026; data expected in the first half of 2027.
• Minor point. Forward-looking: it has not happened yet and may not happen.ELA822 patient trial planned for mid-2027 in T cell-mediated immune disorders.

Negative

• Major pointIPO share issuance dilutes existing shareholders.
• Moderate point$23.9 million net loss reported for the third quarter of 2026.
• Minor point$17.3 million research and development expenses incurred in the third quarter of 2026.
• Minor point$7.8 million general and administrative expenses incurred in the third quarter of 2026.
• Minor pointRegulatory approval remains a condition for the planned mid-2027 ELA822 patient trial.

News Explained

Electra reports objective tumor responses in all eight sHLH patients with underlying T- or B-cell lymphoma who had assessments across the Phase 1b trial and Expanded Access Program, including complete responses in seven; these results are separate from its ongoing T/NK malignancy trial.

Key Figures

Cash, cash equivalents and marketable securities: $402.5 million Net IPO proceeds: $320.0 million Cash runway: Into 2029 +5 more

Cash, cash equivalents and marketable securities

$402.5 million

As of September 30, 2026

Net IPO proceeds

$320.0 million

September 2026 IPO; after specified offering expenses

Cash runway

Into 2029

Expected support for planned operations

R&D expenses

$17.3 million

Third quarter of 2026

G&A expenses

$7.8 million

Third quarter of 2026

Net loss

$23.9 million

Third quarter of 2026

Overall survival

100%

At eight weeks in 12 frontline patients with malignancy-associated HLH

Overall response rate

100%

At the week four assessment in 12 frontline patients with malignancy-associated HLH

Key Terms

monoclonal antibody, placebo-controlled, expanded access program, secondary hemophagocytic lymphohistiocytosis

4 terms

monoclonal antibody medical

"ipsoprubart, is a novel pan-SIRP monoclonal antibody"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

placebo-controlled medical

"initiated a randomized, placebo-controlled Phase 1 trial"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

expanded access program regulatory

"across the Phase 1b trial and Expanded Access Program"

A program that allows patients with serious or life‑threatening conditions to receive an experimental drug or therapy before it is fully approved by regulators, when they cannot join clinical trials. Investors care because expanded access can change a treatment’s market perception, create early real‑world safety or demand signals, and affect regulatory timelines and potential revenue — like a pre‑order system that also reveals how the product performs outside controlled testing.

secondary hemophagocytic lymphohistiocytosis medical

"in development for secondary hemophagocytic lymphohistiocytosis (sHLH)"

A severe, life‑threatening hyperinflammatory syndrome in which the immune system becomes overactivated—macrophages and certain T cells proliferate and release large amounts of cytokines—leading to widespread tissue damage. Secondary hemophagocytic lymphohistiocytosis (secondary HLH) occurs when this process is triggered by an underlying condition such as an infection, cancer (particularly blood cancers), or an autoimmune disorder, rather than by an inherited genetic defect; common features include high fever, low blood cell counts, very high ferritin, liver dysfunction, enlargement of the spleen or liver, and evidence of hemophagocytosis on bone marrow or other tissue samples. The term is a clinical/pathologic diagnosis defined by a combination of symptoms, laboratory abnormalities, and often tissue findings, and it is distinct from primary (genetic) HLH because it is driven by an identifiable external trigger rather than a congenital immune defect.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Ipsoprubart Advancing in Global Registrational Program as Potential First Treatment for sHLH Broadly; Enrollment Completion Expected in Second Half of 2027

Ipsoprubart Therapeutic Expansion Underway in Phase 1 Trial for T/NK Cell Malignancies, with Initial Data Expected in the Second Half of 2027

ELA822 Healthy Volunteer Data Expected in the First Half of 2027, with Patient Trial Initiation Planned for Mid-2027

Completed $350 Million IPO to Fund Advancement of SIRP-Targeting Portfolio

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc. (Nasdaq: ETRA), a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, today reported financial results for the third quarter ended September 30, 2026 and provided an overview of its portfolio and recent business highlights.

“Our recent IPO positions Electra to build on our first-mover advantage in SIRP-targeted precision immune cell depletion,” said Kathy Dong, PharmD, MBA, President and Chief Executive Officer of Electra Therapeutics. “Our deep expertise in SIRP biology and proprietary library of SIRP-targeting antibodies enable us to selectively address distinct pathogenic immune cell populations, creating therapeutic optionality across immune-mediated diseases and cancer. Building on compelling clinical data in sHLH, we are advancing ipsoprubart through a global registrational program and evaluating its potential in T/NK cell malignancies. With ELA822 now in Phase 1, we are advancing multiple programs with the potential to benefit patients and create value for our stakeholders. We anticipate several important milestones in 2027, including ELA822 healthy volunteer data expected in the first half of the year, followed by ipsoprubart data in T/NK cell malignancies and completion of enrollment in the sHLH registrational program in the second half.”

Electra’s novel approach targets signal regulatory proteins (SIRP), a family of cell surface receptors whose expression increases upon activation in specific immune cell populations. This approach is designed to selectively deplete disease-driving immune cells while preserving normal immune function. By offering a more targeted alternative to broad immunosuppression, this approach has the potential to bring greater precision to the treatment for immune-mediated diseases, much as precision oncology has transformed cancer care.

Portfolio Overview

• Ipsoprubart Global Registrational Development for sHLH: The company’s lead product candidate, ipsoprubart, is a novel pan-SIRP monoclonal antibody in development for secondary hemophagocytic lymphohistiocytosis (sHLH), designed to selectively deplete the pathogenic SIRPα/b1-positive myeloid cells and SIRPg-positive T cells characteristic of sHLH.
  • In a Phase 1b trial, ipsoprubart was generally well tolerated and demonstrated 100% overall survival at eight weeks and a 100% overall response rate at the week four assessment in 12 frontline patients with malignancy-associated HLH, the largest subset of sHLH and the population with the poorest outcomes.
  • The company’s global registrational program comprises SURPASS, a Phase 2/3 trial in newly diagnosed, treatment-naïve sHLH patients, and COMPASS, a retrospective natural history study designed to provide an external control comparator, with enrollment completion expected in the second half of 2027.
    
    
• ASH Abstract Acceptances: Two abstracts, including an analysis of healthcare claims data and preclinical data on SIRPα/β1/γ expression in pathogenic immune cells, have been accepted for poster presentations at the 2026 American Society of Hematology Annual Meeting (ASH) on December 13, 2026, from 6:00–8:00 p.m. CT. Presentation details are as follows:
  
  • Title: Increasing burden of secondary hemophagocytic lymphohistiocytosis in the United States: A national-claims analysis of associated conditions, treatments, and care patterns, 2016-2025
    • Abstract number: 4454
    • Session: 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II
  • Title: SIRPα/β1/γ expression is enriched on pathogenic immune cell populations in adults with secondary hemophagocytic lymphohistiocytosis
    • Abstract number: 2965
    • Session: 201. Granulocytes, Monocytes, and Macrophages: Poster II
      
      
• Ipsoprubart for T Cell Malignancies: Ipsoprubart is also being evaluated as single-agent therapy in patients with relapsed/refractory T/NK cell malignancies.
  
  • Among eight sHLH patients with underlying T- or B-cell lymphomas and available objective tumor response assessments across the Phase 1b trial and Expanded Access Program, all eight patients had an objective tumor response and seven had complete responses.
  • Based on this anti-tumor activity, the company is conducting an ongoing Phase 1 trial in patients with relapsed/refractory T/NK malignancies, with initial data expected in the second half of 2027.
    
    
• ELA822 for Chronic Immune and Inflammatory Diseases: ELA822 is a novel SIRPγ-specific antibody in development for chronic T cell-mediated immune and inflammatory diseases, designed to selectively deplete activated, pathogenic T cells while sparing naïve and regulatory T cells.
  
  • In nonclinical models of giant cell arteritis and graft-versus-host disease, ELA822 reduced cytotoxic T cell infiltration into tissues and inflammatory cytokine production, with improvements in disease activity and survival.
  • In September 2026, Electra initiated a randomized, placebo-controlled Phase 1 trial of ELA822 in healthy volunteers, with data expected in the first half of 2027. The company plans to initiate a first-in-disease trial in patients with T cell-mediated immune disorders in mid-2027, subject to regulatory approval.
    
    

Third Quarter 2026 Financial Results

• Cash Position: Cash, cash equivalents, and marketable securities totaled $402.5 million as of September 30, 2026, including $320.0 million in net proceeds from the company’s September 2026 IPO, after deducting underwriting discounts, commissions and other offering expenses paid or payable. Electra expects its current cash position to support planned operations into 2029.
• R&D Expenses: Research and development (R&D) expenses were $17.3 million for the third quarter of 2026.
• G&A Expenses: General and administrative (G&A) expenses were $7.8 million for the third quarter of 2026.
• Net Loss: Net loss totaled $23.9 million for the third quarter of 2026.
  
  

About Electra Therapeutics
Electra Therapeutics is a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer. The company’s novel approach targets signal regulatory proteins (SIRP), a family of cell surface receptors whose expression is restricted to specific immune cell populations and increases upon activation, to enable selective depletion of disease-driving cells while preserving normal immune function. The company’s lead product candidate, ipsoprubart (ELA026), is a novel pan-SIRP monoclonal antibody currently in a global registrational program for secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory syndrome for which there are no broadly approved therapies and survival has remained consistently poor over the past two decades. Ipsoprubart is also being evaluated in a Phase 1 clinical trial in patients with relapsed/refractory T/NK cell malignancies. ELA822, the company’s second clinical-stage product candidate, is a novel SIRPγ-specific antibody being developed for a broad range of chronic T cell-mediated immune and inflammatory diseases. For more information, please visit electra-therapeutics.com and follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements regarding: the therapeutic potential of ipsoprubart (ELA026) and ELA822; the design, timing and results of clinical trials, including anticipated enrollment completion and data readouts; regulatory plans; and the period through which Electra expects its cash to fund operations. Words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will” and similar expressions identify forward-looking statements. These statements reflect management’s current expectations and involve risks and uncertainties that could cause actual results to differ materially. These include:

• the uncertainty of clinical development;
• the risk that results from early or small trials may not predict later results;
• delays in patient enrollment, particularly in rare diseases;
• whether regulators will accept Electra’s registrational program design, including its external control study, to support approval;
• reliance on third parties for manufacturing and clinical trials;
• Electra’s ability to protect its intellectual property;
• Electra’s history of losses and need for additional capital.
  
  

These and other risks are described under “Risk Factors” in Electra’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 and its other SEC filings. Forward-looking statements speak only as of the date of this release. Electra undertakes no obligation to update them, except as required by law.

Contacts:
Investor Contact:
Renee Leck, THRUST
Renee@thrustsc.com

Media Contact:
Sarah Sutton, THRUST
sarah@thrustsc.com

Condensed Statements of Operations (Unaudited)
		THREE MONTHS ENDED SEPTEMBER 30,								NINE MONTHS ENDED SEPTEMBER 30,
			2026				2025				2026				2025
Operating expenses:
Research and development		$	17,268			$	14,901			$	58,905			$	33,693
General and administrative			7,793				1,813				16,386				7,734
General and administrative – related party			—				308				—				964
Total operating expenses			25,061				17,022				75,291				42,391
Loss from operations			(25,061	)			(17,022	)			(75,291	)			(42,391	)
Other income (expense), net:
Interest income			1,133				232				2,453				569
Interest expense – related party			—				(1,293	)			—				(1,620	)
Other income (expense)			—				(9	)			(2	)			(11	)
Total other income (expense), net			1,133				(1,070	)			2,451				(1,062	)
Net loss		$	(23,928	)		$	(18,092	)		$	(72,840	)		$	(43,453	)
Deemed dividend to Series C redeemable convertible preferred stockholders			—				—				(9,675	)			—
Net loss attributable to common stockholders		$	(23,928	)		$	(18,092	)		$	(82,515	)		$	(43,453	)
Net loss per share attributable to common stockholders, basic and diluted		$	(3.47	)		$	(616.86	)		$	(35.24	)		$	(1,481.57	)
Weighted-average common shares outstanding, basic and diluted			6,889,670				29,329				2,341,239				29,329

Condensed Balance Sheets (Unaudited)
		September 30,				December 31,
			2026				2025
Cash, cash equivalents and marketable securities		$	402,535			$	86,518
Working capital (1)			389,954				85,760
Total assets			410,822				99,368
Total liabilities			17,917				11,208
Convertible preferred stock			—				251,602
Common Stock			6				—
Accumulated deficit			(245,818	)			(172,978	)
Total stockholders’ equity (deficit)			392,905				(163,442	)

1. Working capital is defined as total current assets less total current liabilities. See our financial statements and the related notes thereto included in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 for further details regarding our current assets and current liabilities.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Electra Therapeutics' third-quarter 2026 financial results?

Electra reported a $23.9 million net loss, with research and development expenses of $17.3 million and general and administrative expenses of $7.8 million. Cash, cash equivalents and marketable securities totaled $402.5 million at September 30, 2026.

When does Electra Therapeutics expect its next clinical milestones?

Electra expects ELA822 healthy-volunteer data in the first half of 2027 and initial ipsoprubart T/NK malignancy data in the second half. Enrollment completion in the ipsoprubart sHLH registrational program is expected in the second half of 2027. An ELA822 patient trial is planned for mid-2027, subject to regulatory approval.

How is Electra Therapeutics' ipsoprubart sHLH registrational program designed?

The program combines SURPASS, a Phase 2/3 trial in newly diagnosed, treatment-naïve sHLH patients, with COMPASS, a retrospective natural history study designed to provide an external comparison group.

What tumor responses supported Electra Therapeutics' ipsoprubart expansion into T/NK malignancies?

All eight patients with available objective tumor assessments had an objective response, and seven had complete responses. These patients had sHLH with underlying T- or B-cell lymphomas and were treated across the Phase 1b trial and Expanded Access Program. Ipsoprubart is now being evaluated as a single agent in relapsed or refractory T/NK malignancies.